Docebo (DCBO) EBITDA (2019 - 2026)

Docebo has reported EBITDA for 8 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 18.89% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $21.3 million (up 3.63% YoY), and the FY2025 full-year result was $23.2 million, down 0.73% from the prior year.
• EBITDA for Q1 2026 stood at $1.7 million, down from $9.3 million in the prior quarter.
• The five-year high for EBITDA was $9.3 million in Q4 2025, with the low at -$1.5 million in Q2 2023.
• Historically, EBITDA has averaged $3.7 million across 5 years, with a median of $3.7 million in 2022.
• Annual changes were most pronounced in 2023 — EBITDA tumbled 148.0% — and 2024, when it soared 2010.7%.
• Docebo's EBITDA stood at $2.5 million in 2022, then soared by 145.39% to $6.3 million in 2023, then jumped by 46.51% to $9.2 million in 2024, then advanced by 1.92% to $9.3 million in 2025, then tumbled by 81.34% to $1.7 million in 2026.
• The last three EBITDA figures came in at $1.7 million (Q1 2026), $9.3 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.